Fredrik Schjesvold
- Hematology top 1%
- Multiple Myeloma Research and Treatments 86
- Oncology top 5%
- Peptidase Inhibition and Analysis 28
- Cancer Treatment and Pharmacology 23
- CAR-T cell therapy research 7
- Genetics top 10%
- Molecular Biology top 10%
- Protein Degradation and Inhibitors 40
- Immunology top 10%
- Immunotherapy and Immune Responses 6
-
- Monoclonal and Polyclonal Antibodies Research 8
-
- HIV/AIDS drug development and treatment 6
- Co-authors
- Meletios Α. DimopoulosPhilippe MoreauJesús F. San MiguelMichèle CavoPieter SonneveldRoman HájekEvangelos TerposSonja Zweegman
- Cited by
- HematologyOncologyGenetics
- Journals
- Journal of Clinical Oncology (11 papers)SHILAP Revista de lepidopterología (5 papers)Blood (25 papers)
- Partner nations
- NorwaySpainUnited States
In The Last Decade
Fredrik Schjesvold
88 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 91
- Hematology 1.0k
- Oncology 809
- Genetics 121
- Molecular Biology 766
- Immunology 230
Countries citing papers authored by Fredrik Schjesvold
This map shows the geographic impact of Fredrik Schjesvold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fredrik Schjesvold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fredrik Schjesvold more than expected).
Fields of papers citing papers by Fredrik Schjesvold
This network shows the impact of papers produced by Fredrik Schjesvold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fredrik Schjesvold. The network helps show where Fredrik Schjesvold may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fredrik Schjesvold, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 1 | |
| 4 | 2025 | 0 | |
| 5 | 2025 | 0 | |
| 6 | 2024 | 9 | |
| 7 | 2024 | 4 | |
| 8 | 2024 | 1 | |
| 9 | 2024 | 1 | |
| 10 | 2024 | 1 | |
| 11 | 2024 | 2 | |
| 12 | 2023 | 3 | |
| 13 | 2023 | 12 | |
| 14 | 2023 | 5 | |
| 15 | 2023 | 16 | |
| 16 | 2022 | 14 | |
| 17 | 2021 | 1 | |
| 18 | Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†breakdown → | 2021 | 460 |
| 19 | 2020 | 4 | |
| 20 | Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial | 2017 | 0 |
About Fredrik Schjesvold
Fredrik Schjesvold is a scholar working on Hematology, Oncology and Molecular Biology, having authored 103 papers that have together received 1.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (86 papers), Protein Degradation and Inhibitors (40 papers), Peptidase Inhibition and Analysis (28 papers), Cancer Treatment and Pharmacology (23 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), CAR-T cell therapy research (7 papers), Immunotherapy and Immune Responses (6 papers) and HIV/AIDS drug development and treatment (6 papers). The work is most often cited by research in Hematology (1.0k citations), Oncology (809 citations) and Genetics (121 citations). Fredrik Schjesvold has collaborated with scholars based in Norway, Spain and United States. Frequent co-authors include Meletios Α. Dimopoulos, Philippe Moreau, Jesús F. San Miguel, Michèle Cavo, Pieter Sonneveld, Roman Hájek, Evangelos Terpos, Sonja Zweegman, María‐Victoria Mateos and Thierry Façon. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.